Datoo MS, Natama, MH, et al. - In this study, a new candidate vaccine for safety and efficacy was evaluated. Researchers designed a double-blind, randomized, controlled, phase 2b trial administering the low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM) to children aged 5–17 months in Nanoro, Burkina Faso—a highly seasonal malaria transmission setting. They screened a total of 498 children aged 5–17 months, and 48 were excluded between May 7 and June 13, 2019. R21/MM was found to be safe and very immunogenic in African children and exhibits promising high-level efficacy.